Tranexamic acid for surgical bleeding

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Ker, Katharine ^a   Roberts, Ian ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

BLOOD TRANSFUSION; CARDIOVASCULAR RISK; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDITORIAL; HEART INFARCTION; HUMAN; OPERATIVE BLOOD LOSS; PRIORITY JOURNAL; SURGICAL RISK; THROMBOSIS; BLOOD LOSS, SURGICAL; FEMALE; HIP REPLACEMENT; KNEE REPLACEMENT; MALE; PROCEDURES;

ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD LOSS, SURGICAL; FEMALE; HUMANS; MALE; TRANEXAMIC ACID;

EID: 84907363144     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4934     Document Type: Editorial

References (11)

1. National Joint Registry for England & Wales. 10th annual report, 2013. www.njrcentre.org.uk/njrcentre/Reports,PublicationsandMinutes/ Annualreports/tabid/86/Default.aspx.
2. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054.
3. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.
4. VISION Study Investigators. Myocardial injury after noncardiac surgery: a large international prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 2014;120:564-78.
5. Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014;349:g4829.
6. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001;357:373-80.
7. Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol 2013;42:1012-4.
8. Royal College of Paediatrics and Child Health. Major trauma and the use of tranexamic acid in children. Evidence statement, 2012. www.rcpch.ac.uk/ system/files/protected/page/121112-TXA%20evidence%20statement-final%20v2.pdf.
9. Cyklokapron Injection. Summary of product characteristics. Updated 29 Nov 2012.
10. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23-32.
11. Roberts I. Scientific letter: could tranexamic acid use in surgery reduce perioperative myocardial infarction? Heart 2013;99:1785.